University of Hertfordshire

  • Ying Gue
  • Nikolaos Spinthakis
  • Mohamed Farag
  • Jacek Kubica
  • Jolanta M Siller-Matula
  • Manivannan Srinivasan
  • Diana Gorog
View graph of relations
Original languageEnglish
JournalClinical Pharmacology & Therapeutics
Early online date28 Jan 2020
DOIs
Publication statusE-pub ahead of print - 28 Jan 2020

Abstract

Opiates are the traditional analgesics used in patients with ST-elevation myocardial infarction (STEMI). Pharmacodynamic studies indicate that opiates delay the absorption of orally administered P2Y 12 inhibitors and the onset of platelet inhibition. Whether these negative effects on platelet inhibition have an impact on clinical outcomes is unclear. A systematic review and meta-analysis was performed searching PubMed, MEDLINE, and Cochrane Central Register of Controlled Trials to identify studies comparing morphine and no-morphine treatment in STEMI patients undergoing primary percutaneous coronary intervention. The primary end point was the occurrence of in-hospital myocardial infarction, and secondary end points were in-hospital stroke and death. Four observational studies were identified, including 3,220 patients with STEMI. Morphine-treated patients had a higher unadjusted rate of reinfarction compared with patients not receiving morphine (1.5% vs. 0.67%, odds ratio (OR) 2.41; 95% confidence interval (CI), 1.11–5.21; P = 0.03). Unadjusted mortality rate was lower in morphine-treated patients (1.7% vs. 4.2%, OR 0.43, 95% CI, 0.23–0.81; P = 0.009). Exclusion of the study with baseline differences between groups showed more frequent reinfarction in the morphine group, but this was no longer statistically significant (1.3% vs. 0.5%, OR 2.02; 95% CI, 0.39–10.43; P = 0.40). There was no difference in stroke according to morphine treatment. Patients pretreated with morphine appear to have a higher rate of reinfarction than patients not receiving morphine. This may be attributable to opiate-related delay in P2Y 12 inhibitor absorption and resultant delay in onset of platelet inhibition. These concerning findings indicate the need for prospective, randomized trials to assess the impact of opiates on clinical outcomes in STEMI.

Notes

© 2020 American Society for Clinical Pharmacology and Therapeutics. This is the peer reviewed version of the following article: Impact of pre-admission morphine on re-infarction 1 in patients with STEMI 2 treated with PPCI: a meta-analysis, which has been published in final form at https://doi.org/10.1002/cpt.1798 purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

ID: 18690551